Somayeh Mahmoodi Baram, Saeed Karima, Somayeh Shateri, Abbas Tafakhori, Akbar Fotouhi, Behnam Safarpour Lima, Shima Rajaei, Meisam Mahdavi, Hessam Sepasi Tehrani, Vajiheh Aghamollaii, Seyed Hossein Aghamiri, Behnam Mansouri, Sina Gharahje, Samaneh Kabiri, Maryamosadat Hosseinizadeh, Shima Zare Shahamati, Amir Taher Alborzi
Ischaemic stroke represents one of the main causes of disability. According to the broad investigations, it is widely assumed that the contribution of inflammatory mediators is strongly involved in its pathogenesis. Hence, it seems that stroke treatment needs more efficient and inflammatory-targeted compounds to modulate inflammatory-related pathways. Such strategies paved the way to achieve better clinical outcomes along with conventional therapies. Boswellic acids (BAs), the main bioactive compounds of Boswellia sp...
December 2019: Inflammopharmacology